

## Drug Monograph

Drug Name: **Hydroxychloroquine tablet**  
 Drug Class: **Immunologic Agents: Disease-Modifying Antirheumatic Drug (DMARD)**  
 Prepared For: MO HealthNet  
 Prepared By: Conduent

**New Criteria**

**Revision of Existing Criteria**

### Executive Summary

**Purpose:** The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

**Dosage Forms:** Hydroxychloroquine is now available in a 100 mg, 300 mg, and 400 mg oral tablet.

**Manufacturer:** Distributed by: Accord Healthcare, Inc. Durham, NC 27703.

**Indications:** Hydroxychloroquine is indicated for:  
 1) The treatment of uncomplicated malaria due to *P. falciparum*, *P. malariae*, and *P. vivax*  
 2) The treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults  
 3) The treatment of acute and chronic rheumatoid arthritis in adults.

**Costs:** For 60 of the 100 mg tablets: \$17.09; 60 of the 300 mg tablets: \$51.26; and for 60 of the 400 mg tablets: \$68.35 Wholesale Acquisition Cost

**Summary of Findings:** The MO HealthNet Division recommends prior authorization status for this product.

**Status Recommendation:**  Clinical Edit  PA Required  
 Open Access  PDL

**Type of PA Criteria:**  Appropriate Indications  Non-Preferred  
 No PA Required  Preferred

Prepared by: April Ash, PharmD  
 Date: September 30, 2021